Myriad Genetics, Inc. (Nasdaq: MYGN) announced an expanded companion diagnostics (CDx) research collaboration with AbbVie, Inc. to support the development ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE